Jose Muñoz-Langa1, Javier De Castro2, Pere Gascó3, Alfredo Sanchez4, Emilio Esteban5, Jose Manuel Gasent6, Isidoro Barneto7, Joaquin Montalar8, Angel Artal9, Sara Vidal10. 1. 1Hospital Doctor Peset, Valencia, Spain. 2. 2Hospital La Paz, Madrid, Spain. 3. 3Hospital Clinic i Provincial, Barcelona, Spain. 4. 4Hospital Provincial de Castellón, Spain. 5. 5Hospital Central Asturias, Oviedo, Spain. 6. 6Hospital Marina Alta, Denia, Spain. 7. 7Hospital Reina Sofía, Murcia, Spain. 8. 8Hospital La Fé, Valencia, Spain. 9. 9Hospital Miguel Servet, Zaragoza, Spain. 10. 10Jansssen-Cilag, Madrid, Spain.
Abstract
AIM: Providing epidemiological data and treatment of anemia in lung cancer patients undergoing first-line chemotherapy. METHODS: Epidemiological, observational, retrospective and multicenter study carried out at 30 sites throughout Spain. RESULTS: The prevalence of anemia (hemoglobin [Hb] level <12 g/dl) was 18.3% and the incidence 80.7%. Mean Hb levels were 13.4 g/dl (95% Cl: 13.2-13.6) and 11.5 g/dl (95% Cl: 11.3-11.7) at starting and at the end of chemotherapy, respectively. Of the 294 patients with anemia, 174 (59.2%) were treated. Erythropoiesis-stimulating agents were given to 90.2% patients, alone in 31.6% and combined iron in 39.7%, transfusion in 9.2% and iron and transfusion in 9.8%. CONCLUSION: These results suggest an appropriate and rational use of erythropoiesis-stimulating agents in the treatment of chemotherapy-associated anemia in lung cancer patients. [corrected].
AIM: Providing epidemiological data and treatment of anemia in lung cancerpatients undergoing first-line chemotherapy. METHODS: Epidemiological, observational, retrospective and multicenter study carried out at 30 sites throughout Spain. RESULTS: The prevalence of anemia (hemoglobin [Hb] level <12 g/dl) was 18.3% and the incidence 80.7%. Mean Hb levels were 13.4 g/dl (95% Cl: 13.2-13.6) and 11.5 g/dl (95% Cl: 11.3-11.7) at starting and at the end of chemotherapy, respectively. Of the 294 patients with anemia, 174 (59.2%) were treated. Erythropoiesis-stimulating agents were given to 90.2% patients, alone in 31.6% and combined iron in 39.7%, transfusion in 9.2% and iron and transfusion in 9.8%. CONCLUSION: These results suggest an appropriate and rational use of erythropoiesis-stimulating agents in the treatment of chemotherapy-associated anemia in lung cancerpatients. [corrected].